David Doster, Amsel Medical - Mechanical Surgical Clamping Technology | LSI USA '24

David Doster  0:03  
So imagine a world where a majority of the population is 60 years of age or older, it's going to happen. It's estimated that 1.4 billion people will be the age of 60 and older. Now realize that 50% of adults over the age of 60 have some type of venous disease, superficial venous disease, also known as varicose veins. I also want you to think about this 80% of fatalities in the military happen in a pre hospital environment. 60% of those are caused by trauma, or hemorrhage, hemorrhage. My name is David doster. I'm the CEO of Amsoil. Medical, saving lives saving lives is our mission. So why don't we talk about, you know, these two different segments, right? I'm gonna talk about our technology which can be used in different areas. We're seeking a $10 million B series. And we're looking to be 10x rate of return in two to three years, based on some key factors. We have 15 patents, patented technology, we have three FDA clearances, we have a leadership team with experience of people that have been there, done that, and we have high projected revenue growth. So I'm talking about three different verticals within our technology. One is going to be what I talked about earlier, the treatment of varicose veins or advanced venous disease. We currently have FDA approvals around this product, large market large growth, or other vertical is trauma. This is a temporary occluder. The first product is going to be for permanent occlusion. The second one is for temporary occlusion. And this is being paid for by multiple grants within the military. And then we also have an approval for laparoscopic robotic and there's opportunities within that markets as well. So advanced venous disease right what did we what was I talking about there? So remember the the numbers 50% of adults over the age of 60 are going to have some type of varicose veins, advanced venous disease, all the technologies that are out there today and I've been a part of it is treating pretty much you know, C to varicose veins and the segment our product can treat the advanced venous disease which is important there's there's billions of dollars spent just on wound care, not on wound healing. So there's an opportunity there for us. Again, large markets, I don't have to reiterate that our technology is a clamping technologies delivered through an 18 gauge needle transfixes The vessel seals behind it atraumatic closes up the vessel. It's better explained in this ultrasound or I'm sorry, in this animation, as you can see here, you go through the vessel utilizing ultrasound, you launch your distal clamp Unchi unsheathed your proximal clamp, this is a nitinol clamp and lock the two together. And you can close the flow that easy that elegant that quick, right but it's not just an animation. We've already treated humans we've done our first inhuman safety study, we've got two year dwell time, we were able to treat patients with our clinical prototype that you can see here on the left side of the screen, two handed prototype we were able to close vessels and within under 10 minutes, right high safety profile. And and then again, we had a high quality of life outcomes with the patients. So what are the next steps was to design? What did we learn from that clinical study, two handed design needed to be single handed design needed to have a super sharp needle needed to be echogenic. We've we've done that we've put this through some human factors some haptics we put this in the hands of physicians, this design is finalized, ready to go. We've got a reimbursement pathway. We have FDA clearances, and now we're ready just gearing up for a manufacturing vial volume. So this product once we start manufacturing, we can release and start selling. And again, there's some pretty significant comps in this area right there. This market tends continues to grow and be big when we look at it. The one of the earlier acquisitions in this by Medtronic or previously Covidien was with Venus. And that was a large acquisition. But most recently why I brought up Venus in the early 2000s was because BG just bought them clothes. It's a knockoff of that product. Right? It's not growing in the market. It's not increasing market share. It's just taking what Medtronic does and increasing it. So we feel with our product that could drop into any of these companies bags, we'd be frenemies, right. We're gonna expand the market, grow the market, give them something else to to treat. There's a great opportunity. And in fact, we have several investors that work for these companies that are investing in this technology. And then on the two homicide, there was a recent acquisition for half a billion dollars. And I'll talk about trauma here in a second. So trauma, right, why am I segmenting into trauma? So using that same clamping technology, you could go in temporary closed the vessel down. Right. So again, think of it as a arterial specific tourniquet. And these the date is big, right. So when you look at the fatalities within the military that happened in a pre hospital environment, there's really no way to deal with this. And we saw this on October 7, you had 1000 people on the ground. GFW has gunshot wounds, trauma, tourniquets being put on tourniquets not being utilized correctly or not being converted, there's an opportunity for us to deal with this. So even though there's a lot of technologies out there, everything from the gods that we saw, right, that was sold by Teleflex, for half a billion, it's you know, there's still really not a great solution. And with all these technologies that are out there, there's still a great number of fatalities that happen. Let me introduce you our secure clamp to.

So again, we talked about the clamping technology, right, the technology is the clamp. It can be permanent. Here, it's temporary for trauma, right, and it's how this clamp is delivered, or it can be delivered robotically, or laparoscopic, so technologies to clamp with 15 patents on it. Multiple FDA clearances, the delivery or the use is around the delivery system, again, was with the Venus product. We haven't just you know it's not a new concept. We've actually done a preclinical animal study at Madigan Army Center, a lay first year resident was able to put these in and under a minute. And again and successfully deployed these and get hemorrhage control in a simulated trauma. Right, so we're moving this forward. Now this is all paid for which is great about this. And to my investors. This is paid for through grants. Right. We've done multiple SBIR grants with this. We're only one of 8% of companies that make it this far. Right, we've successfully gone through this whole process. And we were just awarded $11 million grant to over the next two years to take this product through commercialization. So again, all non dilutive funding, augmenting my overhead and everything we're doing that will give me a product that is built for my customer, but also allows me to take the pressure off the Venus business and build that out. So this is our timeline. As we start to build this out, once we get funding the Venus product is 10 months away from commercialization. Got a world class team of folks that have been there, done that, right. So I worked for a company angiodynamics We built out the Venus space. I personally was in charge of building out the Venus business for angiodynamics. And again, we took that company public, and we've surrounded ourselves by a team of folks again with the experience of startups. This is the use of proceeds we're raising $10 million. Now we've already raised over 12 million, and again, the non dilutive funding. So again, we've de risked the company we've de risked commercialization by all the clinical work and all the all the things we've done, we have actually 18 patents now and will be in commercial commercialization. Thank you